
-
Vaughan says Crawley 'lucky' to have so many England caps
-
Russian forces claim first foothold in new Ukraine region
-
US envoy says satisfied with Lebanese response on disarming of Hezbollah
-
European stocks, dollar firm as US tariff deadline looms
-
Wimbledon blames 'human error' for embarrassing line-calling glitch
-
Three things learned from British Grand Prix
-
NGOs laud tougher Malaysia plastic trash import laws
-
Mulder makes highest South Africa Test score
-
UK marks London 7/7 attacks as king hails 'spirit of unity'
-
Apple appeals 500-mn-euro EU fine
-
Crowds celebrate Nepal ex-king's birthday in show of support
-
Bali flights nixed after huge Indonesia volcano eruption
-
Hamas, Israel resume talks as Netanyahu set to meet Trump
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM
-
North Korea bars Western influencers from trade fair tour
-
Typhoon Danas kills two, injures hundreds in Taiwan
-
Dutch coastal village turns to tech to find lost fishermen
-
Boxer Chavez's appeal against arrest if deported from US rejected: Mexico prosecutor
-
India captain Gill hailed back home after 'brilliant' Test win
-
The making of Australia's mushroom murders
-
Indonesia volcano spews 18-kilometre ash tower
-
Youthful Chelsea ready for Thiago Silva reunion at Club World Cup
-
Australian inquiry cites racism in Indigenous shooting
-
Djokovic wary despite Wimbledon form, dominant Sinner faces Dimitrov
-
Australian woman found guilty of triple murder with toxic mushrooms
-
Indonesia volcano spews 18-kilometre ash tower: agency
-
Trump says to send first tariff letters on Monday
-
The strange case of Evgeniya Mayboroda, Russia's rebel retiree
-
Asian markets drop as Trump's tariff deadline looms
-
Under-strength Brumbies eye 'big opportunity' against Lions
-
Macron to rekindle relationship with Francophile King Charles on UK visit
-
Trump hosts Netanyahu, hopes for Israel-Hamas deal 'this week'
-
Pressed to confess: Japan accused of 'hostage justice'
-
Demna to bow out at Balenciaga in Paris Haute Couture Week
-
Host of internationals in Australia-New Zealand squad to face Lions
-
Egyptian conservators give King Tut's treasures new glow
-
Mexico defeat USA 2-1 to retain CONCACAF Gold Cup
-
Visa's 24/7 war room takes on global cybercriminals
-
BRICS nations slam Trump tariffs, condemn strikes on Iran
-
Ainos and Solomon Partner to Bring SmellTech Across Asia's Industrial Landscape
-
Amarc Appoints Chief Financial Officer
-
Electric Metals Appoints Brian Savage as Corporate Secretary
-
Mill City Ventures III, Ltd. Increases Yield on $2.5M Credit Facility and Originates New $400K High-Yield Loan
-
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
-
Coder Unveils Enterprise-Grade Platform for Self-Hosted AI Development Environments
-
Clough Global Equity Fund Declares Monthly Cash Distributions for July, August and September 2025 of $0.0650 Per Share
-
Clough Global Opportunities Fund Declares Monthly Cash Distributions for July, August and September 2025 of $0.0501 Per Share

US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
J.Oliveira--AMWN